Parsemus Foundation Press Information
About the Parsemus Foundation
The Parsemus Foundation works to create meaningful improvements in human and animal health and welfare by advancing innovative and neglected medical research. The foundation supports proof-of-concept studies and then seeks to raise awareness of results, to ensure that they change treatment practice rather than disappear into the scientific literature. Many of the studies the foundation supports involve low-cost approaches that are not under patent, and are thus unlikely to be pursued by pharmaceutical companies due to limited profit potential.
The Parsemus Foundation’s main focus has been developing Vasalgel as a non-hormonal male contraceptive. The foundation has partnered with NEXT Life Sciences to complete development of the product and bring it to market. For information on Vasalgel, please contact NEXT Life Sciences.
For information on the development of non-hormonal male contraceptives, visit the Male Contraceptive Initiative.
The foundation also works on pet contraception, including hormone-sparing sterilization options and hormone restoration; noninvasive treatment for benign prostatic hyperplasia (enlarged prostate); prevention of dementia and Alzheimer’s disease; and iron deficiency.
The Parsemus Foundation supported clinical studies on the effectiveness of existing medications to treat COVID infection, including enrollment support for the University of Minnesota’s COVID-Out trial.
The foundation has also supported the development of the nonprofit Menopause Hormone Project to ensure that evidence-based information about menopause hormone therapy is available to women and physicians.
For media coverage of our projects, please contact us at email@example.com
COVID-OUT Clinical Trial Results on Long COVID Announced!
The key findings: The widely available diabetes drug metformin reduced severe outcomes of COVID-19 by 42% and reduced the incidence of Long COVID by 41% if taken shortly after symptoms of COVID-19. Metformin also reduced the amount of SARS-CoV-2 virus.
Background: The COVID-OUT clinical trial was aimed at understanding if safe, commonly available medications may treat COVID-19 symptoms and those of long COVID. The study examined the medications metformin, ivermectin, and fluvoxamine, which are known to decrease inflammatory proteins (cytokines) in the body. This rigorous randomized, controlled clinical trial was conducted by the University of Minnesota under the direction of Dr. Carolyn Bramante.
Funders: The Parsemus Foundation provided pilot funding and enrollment support to the University of Minnesota. Additional major funders include the University of Minnesota Clinical Translational Science Institute, the Rainwater Foundation, FastGrants, and UnitedHealth Group Research and Development.
- Parsemus Foundation COVID webpage
- Parsemus Foundation Press Release
- The Lancet Infectious Diseases Publication
- The University of Minnesota Press Release
- The Atlantic Jan 19, 2023.
- Medscape Feb 21, 2023.
- WebMD Mar 9, 2023.
- Time Mar 16, 2023.
- MedPage Today. Mar 21, 2023.
- BMJ. Jun 8, 2023.
- Yahoo. Jun 8, 2023.
- Star Tribune. Jun 8, 2023.
- US News & World Report. Jun 9, 2023.
- New Scientist. Jun 9, 2023.
- CBC. Jun 10, 2023.
Initial results of COVID-OUT trial, August 18, 2022
Image Files, Videos, and Printable Materials
Parsemus Foundation Logo
Vector-based logo in full color
Vector-based logo in silhouette
Executive And Associate Headshots
Elaine Lissner, Founder and Trustee, Parsemus Foundation and Revolution Contraceptives, LLC
Linda Brent, PhD, MBA, Executive Director, Parsemus Foundation